+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
MALE
ID07189598

Phase III Study of Adaptive Stereotactic Body Radiotherapy With Dose Escalation on the Dominant Intraprostatic Lesion for High-Risk Prostate Cancer

Led by Center Eugene Marquis · Updated on 2026-04-30

390

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of an adaptive prostate Stereotactic Body Radiotherapy SBRT approach that combines Whole Pelvic Radiotherapy WPRT and increased dosing on the Dominant Intraprostatic Lesion DIL compared to standard radiotherapy methods. This study focuses on men with high-risk prostate cancer and includes a 5-year cost-utility analysis using trial data and national health records. The trial is led by Center Eugene Marquis and is designed as a randomized comparison without masking. Participants in the experimental group will receive adaptive stereotactic ultra-fractionated radiotherapy every other day over about 10 days, with a maximum treatment duration of 17 days. The doses delivered include 36.25 Gray in 5 fractions to the prostate gland, up to 50 Gray in 5 fractions to the dominant lesion, 25 Gray in 5 fractions to seminal vesicles, and 25 Gray in 5 fractions to pelvic lymph nodes. The control group will receive either conventional fractionation 78 Gray in 39 fractions or moderate hypofractionation 60 Gray in 20 fractions targeting the prostate gland, seminal vesicles, and pelvic nodes. Throughout the study, participants will be monitored over five years for treatment efficacy, including biochemical and metastatic recurrence-free survival, overall survival, quality of life, and treatment-related toxicity affecting urinary, intestinal, and sexual functions. The primary outcome is the efficacy of the adaptive SBRT approach on the dominant lesion five years after radiotherapy. Extensive imaging and diagnostic tests before treatment, as well as regular follow-ups afterward, will support the assessment of these outcomes.

CONDITIONS

Brief Title

Phase III Adaptive Adaptive Stereostactic Body Radiotherapy (SBRT) With Dose Escalation for High-Risk Prostate Cancer

Research Team

J

Jennifer LE GUEVELOU, DR

R

Renaud DE CREVOISIER, PR

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here